CLINICAL_TRIALS
trial_result
· 2012-09-12
Clinical Trial Update: PT005 MDI Dose Ranging Versus Foradil Aerolizer Study [Phase 2]
Summary
Phase 2 dose-ranging study comparing PT005 MDI to Foradil Aerolizer in chronic obstructive pulmonary disease has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pearl Therapeutics, Inc. | Conditions: Chronic Obstructive Pulmonary Disease | Phase 2 | Status: COMPLETED